Magnetic Resonance Imaging of Breast Cancer

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01035112

Enrollment

500

Registered

2009-12-18

Start date

1995-04-01

Completion date

2027-05-01

Last updated

2026-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Breast Cancer Non-invasive Breast Cancer

Brief summary

To compare magnetic resonance imaging (MRI) with more well established diagnostic imaging techniques to determine which method best finds and defines breast cancer.

Interventions

PROCEDUREMRI

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

21 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Female * Documented breast physical examination, * Documented mammography within 3 months of the MR studies * Palpable or mammographically-detected suspect breast lesions * Women who have already undergone lumpectomy for breast cancer and have post-biopsy/post-radiation changes will be eligible if they have mammographically-detected or palpable breast abnormalities which are sufficiently suspicious to merit core needle or surgical biopsy.

Exclusion criteria

* Male by birth * Able to complete the MR examination. Subjects will be interviewed by one of the investigators for the usual contraindications to * MR contraindications including * Pacemakers * Metallic implants * Severe claustrophobia * Aneurysm clips * Pregnancy * Current lactation * Other conditions precluding proximity to a strong magnetic field. * Received an enhanced MR procedure within 48 hours, * Iodinated contrast within six hours, * Known sensitivity to MR contrast agents, * Not likely to complete the study in full or * Other clinical reason which would preclude participation in the protocol.

Design outcomes

Primary

Measure	Time frame
To compare magnetic resonance imaging (MRI) with more well established diagnostic imaging techniques to determine which method best finds and defines breast cancer.	Length of one MRI scan

Countries

United States

Contacts

CONTACTJocelyn Steffan

jsteffen@stanford.edu650-725-1812

PRINCIPAL_INVESTIGATORBruce L Daniel

Stanford University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 2, 2026